Planes, Trains, and VTEs

Simple recommendations can help mitigate risk for travel-related blood clots In November 2011, hematologist Suely Rezende, MD, PhD, deplaned from a flight from Lisbon to São Paulo, where she was scheduled to speak at a...

Online Exclusives

New Policy Takes Aim at “Secret” Hospital and Insurer Negotiations

In a proposed rule, the U.S. Department of Health and Human Services (HHS) announced it is considering requiring U.S. hospitals and insurers to publicize...

Opioid Prescriptions Down, But Pain May Be Up

Since the Centers for Disease Control and Prevention (CDC) issued strict guidelines to curb inappropriate patterns of opioid prescription, the prescribing rate has declined....

News

From the Blood Journals

Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in...

For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...
WIB_icon

Evaluating Midostaurin Plus Intensive Chemotherapy in Older Patients With AML

Midostaurin plus intensive chemotherapy, followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent midostaurin maintenance therapy, was improved survival outcomes in patients with newly...

Multimedia

Pulling Back the Curtain: Dan Pollyea, MD, MS

In more from our interview with Dan Pollyea, MD, MS, he shares what he learned from growing up watching his father practice medicine and the simple...

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...

Ravulizumab: A New Treatment Option for PNH?

Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda

Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings.

On Location

A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?

A study of patients with bone marrow failure (BMF) and short telomeres found that a...

Salvage Transplant Versus Continuous Therapy: Insights From the Myeloma ReLApsE Trial

For patients with multiple myeloma (MM) that has relapsed following autologous hematopoietic cell transplantation (AHCT),...

Venetoclax Plus R-CHOP Improves Outcomes in BCL2-Positive DLBCL

For the substantial portion of patients with diffuse large B-cell lymphoma (DLBCL) with overexpression of...

Rituximab-Lenalidomide Combo Superior to Rituximab Alone in Relapsed/Refractory Indolent NHL

For patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL), adding lenalidomide to rituximab treatment improved response...

Evaluating Ixazomib Regimens in Patients With Newly Diagnosed Myeloma

Two studies presented at the 2018 ASH Annual Meeting explored the use the oral proteasome...

An ASH Annual Meeting Post-Vivum

“So, what did you learn from ASH?” asked my advisor a couple of weeks after...

Latest Headlines

Advertisement

ASH Directions

ASH Recommends Changes to Continuing Board Certification, and more

ASH Recommends Changes to Continuing Board Certification In December 2018, a commission appointed by the American Board of Medical Specialties (ABMS) and other entities released...

An Advocacy Win for Sickle Cell Disease

An Advocacy Win for Sickle Cell Disease As part of a multifaceted initiative to address the burden of sickle cell disease (SCD) in the U.S....

Sign up for our
eNewsletter!

Boston Children’s Hospital Receives $1.5 million for SCD Research, Fred Hutch Names New Endowed...

Weill Cornell Researchers Awarded $9 Million for Lymphoma Research The National Cancer Institute (NCI) awarded a five-year, $9-million Program Project Grant (P01) to Weill Cornell...

Remembering Evan Sadler and Charles Dobbs, and more

Remembering Evan Sadler (1951 – 2018) Evan Sadler III, MD, PhD, the Lang Professor of Medicine and Chief of Hematology at Washington University in St....

Remembering Peter R. Galbraith and Sir David Weatherall, FDA names Amy Abernethy new Deputy...

Remembering Peter R. Galbraith (1931 – 2018) Peter R. Galbraith, MD, FRCPC, an emeritus professor at Queen’s University in Kingston, Ontario, passed away on October...

Planes, Trains, and VTEs

Simple recommendations can help mitigate risk for travel-related blood clots In November 2011, hematologist Suely Rezende, MD, PhD, deplaned from a flight from Lisbon to...

Is the Era of Traditional Chemotherapy for Hodgkin Lymphoma Over?

Treatment of Hodgkin lymphoma (HL) has been one of the greatest success stories in oncology, with the invention of radiation therapy and combination chemotherapy...

Finding Homes for Orphans

The unique challenges of researching, managing, and developing orphan drugs for rare diseases Rare diseases are having a moment, and not just in the field...